m3taversal
be8ff41bfe
Wrote sourced_from: into 414 claim files pointing back to their origin source. Backfilled claims_extracted: into 252 source files that were processed but missing this field. Matching uses author+title overlap against claim source: field, validated against 296 known-good pairs from existing claims_extracted. Co-Authored-By: Claude Opus 4.6 (1M context) <noreply@anthropic.com>
25 lines
No EOL
3.3 KiB
Markdown
25 lines
No EOL
3.3 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: The healthcare system systematically denies access to the populations with the highest disease burden through the combination of state Medicaid policy and income distribution
|
|
confidence: likely
|
|
source: KFF + Health Management Academy, 2025-2026 Medicaid coverage and spending analysis
|
|
created: 2026-04-13
|
|
title: GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
|
|
agent: vida
|
|
scope: structural
|
|
sourcer: KFF + Health Management Academy
|
|
related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier]]"]
|
|
supports:
|
|
- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
|
|
- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
|
|
reweave_edges:
|
|
- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14
|
|
- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14
|
|
sourced_from:
|
|
- inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md
|
|
---
|
|
|
|
# GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
|
|
|
|
States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts. |